|
PSME4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.03349999949864E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.50139999999244E-06 |
| Normal-vs-Stage2 |
4.704000E-03 |
| Normal-vs-Stage3 |
2.23570000001949E-06 |
| Normal-vs-Stage4 |
2.61779999899403E-08 |
| Stage1-vs-Stage2 |
3.789800E-01 |
| Stage1-vs-Stage3 |
2.914000E-01 |
| Stage1-vs-Stage4 |
1.065880E-02 |
| Stage2-vs-Stage3 |
1.611630E-01 |
| Stage2-vs-Stage4 |
1.091680E-02 |
| Stage3-vs-Stage4 |
1.438160E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.63879999465411E-08 |
| Normal-vs-AfricanAmerican |
7.030000E-04 |
| Normal-vs-Asian |
2.36109999999234E-05 |
| Caucasian-vs-AfricanAmerican |
8.951600E-01 |
| Caucasian-vs-Asian |
5.308000E-01 |
| AfricanAmerican-vs-Asian |
8.058600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.414900E-04 |
| Normal-vs-Female |
3.57880000079192E-08 |
| Male-vs-Female |
1.967770E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.61480000000691E-05 |
| Normal-vs-Age(41-60Yrs) |
1.33799999968431E-08 |
| Normal-vs-Age(61-80Yrs) |
7.98800000000321E-05 |
| Normal-vs-Age(81-100Yrs) |
5.125800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.547800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.772400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.684400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.130800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.735400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.321600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.039800E-03 |
| Classical-VS-Follicular |
4.223800E-02 |
| Classical-VS-Other |
6.337000E-01 |
| Classical-VS-Normal |
4.25470000342543E-08 |
| Tall-VS-Follicular |
1.818040E-03 |
| Tall-VS-Other |
4.349800E-01 |
| Tall-VS-Normal |
9.03539999486114E-08 |
| Follicular-VS-Other |
3.124600E-01 |
| Follicular-VS-Normal |
7.720000E-03 |
| Other-VS-Normal |
8.801600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.73605000000077E-05 |
| Normal-vs-N1 |
1.16819999995688E-06 |
| N0-vs-N1 |
2.325400E-01 |
|
|
